BACKGROUND : Several randomized phase III studies in advanced stage non-small cell lung cancer ( NSCLC ) confirmed the superior response rate and progression-free survival of using epidermal growth factor receptor ( EGFR ) tyrosine kinase inhibitor as first-line therapy compared with chemotherapy in patients with activating EGFR mutations .